Go Pro
→ American retirees will miss THIS. Big Banks just moved in. (From Cedar Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$3.49
+3.9%		$25.14
$1.03
▼
$8.48
$16.33M1.7596,117 shs435,914 shs
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$3.44
-13.4%		$8.81
$3.43
▼
$23.25
$5.67M0.522,830 shs52,758 shs
LianBio stock logo
LIAN
LianBio
$0.05
-5.6%		$0.06
$0.27
▼
$4.99
$5.30M0.231.04 million shs513 shs
Scienture Holdings, Inc. stock logo
SCNX
Scienture
$0.34
-1.1%		$0.39
$0.24
▼
$2.60
$14.13M3.252.25 million shs121,983 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
0.00%-88.27%-86.85%-84.32%-79.73%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
0.00%-71.94%-56.08%-56.33%-77.76%
LianBio stock logo
LIAN
LianBio
0.00%+25.32%+20.39%-69.36%-9.59%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
0.00%-6.73%-25.33%-3.44%-63.12%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$3.49
+3.9%		$25.14
$1.03
▼
$8.48
$16.33M1.7596,117 shs435,914 shs
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$3.44
-13.4%		$8.81
$3.43
▼
$23.25
$5.67M0.522,830 shs52,758 shs
LianBio stock logo
LIAN
LianBio
$0.05
-5.6%		$0.06
$0.27
▼
$4.99
$5.30M0.231.04 million shs513 shs
Scienture Holdings, Inc. stock logo
SCNX
Scienture
$0.34
-1.1%		$0.39
$0.24
▼
$2.60
$14.13M3.252.25 million shs121,983 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
0.00%-88.27%-86.85%-84.32%-79.73%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
0.00%-71.94%-56.08%-56.33%-77.76%
LianBio stock logo
LIAN
LianBio
0.00%+25.32%+20.39%-69.36%-9.59%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
0.00%-6.73%-25.33%-3.44%-63.12%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
1.00
SellN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
2.00
Hold$22.50554.07% Upside
LianBio stock logo
LIAN
LianBio
0.00
N/AN/AN/A
Scienture Holdings, Inc. stock logo
SCNX
Scienture
2.00
Hold$1.50336.05% Upside

Current Analyst Ratings Breakdown

Latest LIAN, CYCN, LEXX, and SCNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2026
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/24/2026
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/13/2026
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/25/2026
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/24/2026
Scienture Holdings, Inc. stock logo
SCNX
Scienture
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$2.07M7.89N/AN/A$2.31 per share1.51
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$710K7.99N/AN/A$2.00 per share1.72
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/A$2.71 per shareN/A
Scienture Holdings, Inc. stock logo
SCNX
Scienture
$430K32.85N/AN/A$1.73 per share0.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-$3.53M-$1.66N/AN/AN/A-170.11%-87.96%-74.86%11/11/2026 (Estimated)
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-$11.90M-$5.10N/AN/AN/AN/A-174.93%-143.89%10/28/2026 (Estimated)
LianBio stock logo
LIAN
LianBio
-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/A
Scienture Holdings, Inc. stock logo
SCNX
Scienture
-$41.51M-$2.10N/AN/AN/AN/A-53.51%-42.47%11/12/2026 (Estimated)

Latest LIAN, CYCN, LEXX, and SCNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Scienture Holdings, Inc. stock logo
SCNX
Scienture
-$0.09-$0.07+$0.02-$0.07$1.96 million$0.34 million
7/13/2026Q3 2026
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-$0.06-$0.08-$0.02-$1.20$0.05 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/AN/AN/AN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/AN/AN/AN/AN/A
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/A
Scienture Holdings, Inc. stock logo
SCNX
Scienture
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/A
0.82
0.82
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/A
10.61
10.61
LianBio stock logo
LIAN
LianBio
N/A
10.06
10.06
Scienture Holdings, Inc. stock logo
SCNX
Scienture
0.15
3.04
2.97

Institutional Ownership

CompanyInstitutional Ownership
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
75.62%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
13.06%
LianBio stock logo
LIAN
LianBio
74.85%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
5.68%

Insider Ownership

CompanyInsider Ownership
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
34.30%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
8.39%
LianBio stock logo
LIAN
LianBio
7.59%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
21.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
304.68 million3.08 millionNo Data
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
71.65 million1.51 millionNot Optionable
LianBio stock logo
LIAN
LianBio
110108.06 million99.86 millionNot Optionable
Scienture Holdings, Inc. stock logo
SCNX
Scienture
N/A41.06 million32.28 millionN/A

Recent News About These Companies

Scienture (NASDAQ:SCNX) Stock Price Up 0.9% - What's Next?
September 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31014050
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3358685/0/en/scienture-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference-on-september-14-2026.html
Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses
August 14, 2026  |  quiverquant.comQ
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345299/0/en/scienture-reports-q2-2026-results-with-approximately-510-sequential-revenue-growth-from-q1-2026-and-significant-improvement-in-operating-performance.html
Scienture Holdings Stock Price History
August 12, 2026  |  investing.comhttps://www.investing.com/equities/trxade-historical-data
Scienture launches Rezenopy as second FDA-approved commercial product
August 12, 2026  |  msn.comhttps://www.msn.com/en-us/money/smallbusiness/scienture-launches-rezenopy-as-second-fda-approved-commercial-product/ar-AA29WnUq
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/12/3343616/0/en/scienture-announces-commercial-launch-and-fulfillment-of-initial-purchase-orders-of-rezenopy-the-highest-dose-fda-approved-naloxone-nasal-spray.html
Scienture Holdings纳洛酮鼻喷雾剂7月将向美批发商发货
July 28, 2026  |  finance.sina.com.cnF
Scienture Holdings stock jumps over 20% pre-market: Here's why
July 10, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/scienture-holdings-stock-jumps-over-20-pre-market-here-s-why/ar-AA27CXrC
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
July 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scienture-announces-commercial-inventory-readiness-120500243.html
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
July 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/09/3324768/0/en/scienture-announces-commercial-inventory-readiness-and-july-shipments-of-rezenopy-naloxone-hydrochloride-to-wholesalers.html
SCNX Share News Today
July 4, 2026  |  uk.investing.comhttps://uk.investing.com/equities/trxade-news
Scienture Holdings (SCNX) Stock Forecast & Price Target
June 25, 2026  |  investing.comhttps://www.investing.com/equities/trxade-consensus-estimates
Scienture Holdings Stock Short Interest Report | NASDAQ:SCNX | Benzinga
June 24, 2026  |  benzinga.comhttps://www.benzinga.com/quote/SCNX/short-interest
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
June 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/18/3314147/0/en/scienture-expands-arbli-payor-coverage-and-commercial-access-adding-approximately-12-5-million-covered-lives-nationwide.html
Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX)
June 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2519934/analysts-conflicted-on-these-healthcare-names-moderna-mrna-and-scienture-holdings-scnx/
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
June 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/09/3308798/0/en/scienture-secures-formulary-coverage-for-rezenopy-with-a-large-national-health-plan-and-expands-commercial-team.html
SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
June 4, 2026  |  accessnewswire.comA
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
June 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/02/3305134/0/en/scienture-receives-u-s-patent-covering-rezenopy-naloxone-hcl-nasal-spray-10-mg-strengthening-intellectual-property-protection-through-2041.html
Scienture Holdings Announces CFO Resignation, Names Interim Successor
May 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/scienture-holdings-announces-cfo-resignation-names-interim-successor?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
Microsoft logo and sign displayed in the lobby of a corporate office building with a glass meeting room.
Microsoft's Maia 300 Chip Targets NVIDIA's AI Dominance
By Chris Markoch | August 16, 2026
Datavault logo displayed in front of an open bank vault door within a server room lined with data streams.
Datavault AI Locks Down CyberCatch in $94M Security Rollup
By Jeffrey Neal Johnson | August 19, 2026
Illuminated Nasdaq logo displayed on a glass building facade, with city skyscrapers reflected around it.
Nasdaq’s 23-Hour Trading Push Could Turn Global Liquidity Into a Growth Engine
By Jeffrey Neal Johnson | August 20, 2026
Block logo overlaid on a coffee shop counter with a Square point-of-sale terminal and card reader.
Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
By Jeffrey Neal Johnson | September 11, 2026
Cyclerion Therapeutics stock logo

Cyclerion Therapeutics NASDAQ:CYCN

$3.49 +0.13 (+3.87%)
Closing price 09/8/2026
Extended Trading
$3.49 0.00 (0.00%)
As of 09/8/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Lexaria Bioscience stock logo

Lexaria Bioscience NASDAQ:LEXX

$3.44 -0.53 (-13.35%)
As of 11:36 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

LianBio stock logo

LianBio NASDAQ:LIAN

$0.05 0.00 (-5.59%)
As of 09/11/2026

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Scienture stock logo

Scienture NASDAQ:SCNX

$0.34 0.00 (-1.12%)
As of 11:37 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas